A Research Guide for
Heart Failure

Heart failure symptoms develop because the heart can’t pump efficiently, causing fluid to back up (congestion) and tissues to receive less blood (low output):

• Shortness of breath (dyspnea): Initially only with exertion, eventually at rest. Worsening when lying flat (orthopnea) and sudden nighttime breathlessness (paroxysmal nocturnal dyspnea) are classic.
• Fatigue and reduced exercise tolerance: The body’s tissues don’t get enough oxygen-rich blood.
• Swelling (edema): Typically in the ankles, legs, and abdomen (ascites) due to fluid retention.
• Rapid or irregular heartbeat: The heart tries to compensate by beating faster.
• Persistent cough or wheezing: Fluid in the lungs.
• Reduced appetite, nausea: Congestion in the liver and gut.
• Difficulty concentrating, confusion: In advanced cases, from reduced brain blood flow.

Heart failure severity is classified using the NYHA functional class system:

• Class I: No symptoms with ordinary activity
• Class II: Mild symptoms with ordinary activity; slight limitation
• Class III: Marked limitation; comfortable only at rest
• Class IV: Symptoms at rest; unable to carry on any activity without discomfort

Natriuretic peptides are the most important blood tests for heart failure. They are released by the heart when it is under stress:

• BNP (B-type natriuretic peptide): Levels above 100 pg/mL suggest heart failure; below 100 makes it unlikely
• NT-proBNP (N-terminal pro-BNP): Levels above 300 pg/mL suggest heart failure in acute settings; age-adjusted thresholds for chronic HF (<50 years: >450; 50–75: >900; >75: >1,800 pg/mL). Below 125 pg/mL makes chronic HF unlikely
• High-sensitivity troponin: Elevated levels suggest ongoing heart muscle injury; helps assess prognosis

Other important blood tests include a complete metabolic panel (potassium, sodium, creatinine, eGFR — critical for medication dosing), complete blood count, thyroid function, iron studies (ferritin and TSAT — iron deficiency is very common in HF), liver function tests, HbA1c, and lipid panel.

For ATTR-CM workup: serum and urine protein electrophoresis with immunofixation (SPEP/UPEP/IFE) and serum free light chains are essential to rule out AL amyloidosis before diagnosing ATTR-CM by bone scan.

A transthoracic echocardiogram (TTE) is the single most important imaging test in heart failure. It is non-invasive (ultrasound of the heart) and provides:

• Ejection fraction (EF): The key number that classifies your HF type
• Chamber sizes: Enlarged left ventricle suggests HFrEF; thickened walls may suggest HFpEF, hypertensive heart disease, or infiltrative disease (amyloid, HCM)
• Diastolic function: How well the heart relaxes and fills — abnormal in HFpEF
• Valve function: Leaking or narrowed valves can cause or worsen HF
• Right heart function: Pulmonary hypertension and right ventricular failure assessment
• Global longitudinal strain (GLS): A sensitive measure of heart muscle function; can detect abnormalities even when EF appears normal; characteristic “apical sparing” pattern in cardiac amyloidosis

Echocardiograms should be repeated when symptoms change significantly, after major medication changes, and before device implantation decisions.

Cardiac MRI (CMR): The gold standard for measuring EF and heart muscle characterization. Late gadolinium enhancement (LGE) identifies scar tissue from heart attacks or inflammation. T1 mapping and extracellular volume (ECV) fraction help diagnose infiltrative diseases like amyloidosis and Anderson-Fabry disease. CMR is recommended when echo is inconclusive or when infiltrative disease is suspected.

Nuclear bone scintigraphy (Tc-99m PYP/DPD/HMDP): This has revolutionized ATTR-CM diagnosis. A radiotracer (Tc-99m pyrophosphate in the US, DPD or HMDP in Europe) is injected and preferentially binds to transthyretin amyloid deposits in the heart. Grading:

• Grade 0: No cardiac uptake → ATTR-CM unlikely
• Grade 1: Mild uptake, less than bone → Possible ATTR-CM; consider further evaluation
• Grade 2: Moderate uptake, equal to bone → Diagnostic for ATTR-CM (if monoclonal protein excluded)
• Grade 3: Strong uptake, greater than bone → Diagnostic for ATTR-CM (if monoclonal protein excluded)

Critical point: A Grade 2 or 3 scan with negative monoclonal protein workup (no AL amyloidosis) has >99% specificity for ATTR-CM — no heart biopsy needed. This non-invasive pathway has led to a surge in ATTR-CM diagnoses.

Coronary angiography or CT coronary angiography: To evaluate coronary artery disease as a cause of HF, especially in HFrEF.

Right heart catheterization: Measures filling pressures directly; essential before heart transplant evaluation and sometimes to confirm HFpEF diagnosis in borderline cases.

Identifying why the heart is failing is crucial because some causes are reversible:

• Coronary artery disease: The most common cause of HFrEF. Revascularization (stent or bypass surgery) can help if significant ischemia or viable myocardium exists
• Hypertension: Long-standing uncontrolled blood pressure is a leading cause of HFpEF
• Valvular heart disease: Severe aortic stenosis or mitral regurgitation may require valve repair/replacement
• Cardiomyopathies: Dilated, hypertrophic, restrictive, or arrhythmogenic — some have specific treatments
• Infiltrative diseases: Cardiac amyloidosis (ATTR or AL), sarcoidosis, hemochromatosis (iron overload)
• Tachycardia-mediated: Uncontrolled rapid heart rhythms (atrial fibrillation, frequent PVCs) can weaken the heart; treating the arrhythmia may reverse the HF
• Toxins: Alcohol, cocaine, anthracycline chemotherapy, trastuzumab
• Thyroid disease: Both hyperthyroidism and hypothyroidism can cause HF
• Peripartum cardiomyopathy: HF developing in the last month of pregnancy or within 5 months of delivery

Ejection fraction (EF) is one of the most important numbers in heart failure care, but it is also one of the most misunderstood. Here is what it actually means and how to interpret changes over time.

What EF measures: EF is the percentage of blood your left ventricle pumps out with each beat. A normal heart ejects 55–70% of the blood it contains. Heart failure with reduced ejection fraction (HFrEF) is defined as EF ≤40%. HF with mildly reduced EF (HFmrEF) is 41–49%, and HF with preserved EF (HFpEF) is ≥50% with evidence of filling abnormalities.

What EF does NOT tell you: A higher EF is not always better, and a lower EF is not always worse, on its own. Your symptoms, exercise tolerance, biomarker levels, and quality of life matter at least as much as the EF number. Many people live full and active lives with an EF of 25–30%. Conversely, some people with HFpEF and a “normal” EF have severe symptoms.

Why EF changes:

• Improvement with treatment: Many people start with an EF of 20–30% and see it recover to 40–55% after 3–12 months on GDMT. This is called “heart failure with improved EF” (HFimpEF) and is a real treatment success.
• If your EF improves, you are not cured: Stopping medications when EF normalizes causes relapse in ~40% of people. The medications are what is keeping your EF up — do not stop them without consulting your cardiologist.
• EF can vary between measurements: Echocardiograms have a measurement variability of about ±5%. A change from 35% to 38% is within the margin of error. Focus on the trend over several measurements rather than any single number.
• Different tests may give different values: MRI is more accurate than echo for measuring EF. If your numbers differ between tests, the MRI value is considered more reliable.

Ask your cardiologist: “What is my EF today compared to when I was first diagnosed? What does the change mean for my treatment?”

Heart failure can run in families. In some cases, an inherited gene variant is the underlying cause of the heart muscle problem. Identifying a genetic cause matters because it changes your own care, informs your family members who may be at risk, and can affect decisions like family planning.

When genetic testing is most likely to find something important:

• You developed HF before age 50 and no other cause (like heart attacks or excessive alcohol) is found
• A parent, sibling, or child has had heart failure, cardiomyopathy, or unexplained sudden cardiac death
• You have significant conduction system disease (AV block, bundle branch block) along with heart failure
• Your doctor suspects a specific genetic condition such as hypertrophic cardiomyopathy (HCM), Fabry disease, or arrhythmogenic cardiomyopathy (ACM)

What a genetic test involves: A simple blood or saliva sample is sent to a specialized laboratory. A panel of 50–100+ heart-related genes is sequenced. Results typically take 3–6 weeks. Your cardiologist or a genetic counselor will review the results with you.

What the results mean:

• Pathogenic variant found: A gene change known to cause heart muscle disease. This confirms a diagnosis, guides your treatment (especially around ICD timing and drug choices), and means family members should be tested.
• Variant of uncertain significance (VUS): A gene change where it is unknown whether it causes disease. This is common and usually does not change treatment. Re-classification over time is possible.
• No variant found: Does not rule out a genetic cause — current panels do not detect everything. Family history should still be taken seriously.

A genetic counselor can help you understand what the result means for you and for sharing information with family members, including adult children who may benefit from cardiac screening.

Sacubitril/valsartan (Entresto) — the preferred ARNI:

• What it does: Combines a neprilysin inhibitor (sacubitril, which boosts beneficial natriuretic peptides) with an ARB (valsartan, which blocks the harmful renin-angiotensin system). A dual-action drug.
• Key trial: PARADIGM-HF showed a 20% reduction in cardiovascular death and a 21% reduction in HF hospitalization compared to enalapril in HFrEF
• Dosing: Start at 24/26 mg or 49/51 mg twice daily; target dose is 97/103 mg twice daily. Requires a 36-hour washout from ACE inhibitors before starting.
• Side effects: Low blood pressure (hypotension), elevated potassium, kidney function changes, rare angioedema
• Monitor: Blood pressure, potassium, creatinine at 1–2 weeks after each dose increase

If ARNI is not tolerated: ACE inhibitors (enalapril, lisinopril, ramipril) or ARBs (valsartan, losartan, candesartan) are alternatives with good evidence.

Only three beta-blockers are proven to reduce mortality in HFrEF:

• Carvedilol (Coreg): 3.125 mg twice daily, titrate to 25 mg twice daily (50 mg twice daily if >85 kg). Non-selective beta-blocker with alpha-blocking properties.
• Metoprolol succinate (Toprol-XL): 12.5–25 mg daily, titrate to 200 mg daily. Beta-1 selective. Note: metoprolol tartrate (Lopressor) is NOT the same — the extended-release succinate formulation must be used.
• Bisoprolol: 1.25 mg daily, titrate to 10 mg daily. Beta-1 selective. Less commonly used in the US but well-studied.

Key points: Start low, increase slowly (double the dose every 2 weeks if tolerated). Patients may feel worse initially (more fatigue, slightly lower blood pressure) before the long-term benefits emerge over weeks to months. Do not stop beta-blockers abruptly.

When to hold or avoid: Severe decompensation (active fluid overload requiring IV diuretics), heart rate below 50, symptomatic low blood pressure, high-degree heart block without a pacemaker.

Mineralocorticoid receptor antagonists block aldosterone, a hormone that promotes harmful fluid retention, inflammation, and scarring of the heart.

• Spironolactone (Aldactone): 12.5–25 mg daily, target 25–50 mg daily. RALES trial: 30% mortality reduction in severe HFrEF. Can cause breast tenderness/enlargement (gynecomastia) in men due to anti-androgen effects.
• Eplerenone (Inspra): 25 mg daily, target 50 mg daily. EMPHASIS-HF trial: 37% reduction in cardiovascular death or HF hospitalization. More selective, no gynecomastia, but more expensive.

Critical safety concern: Both can cause dangerous high potassium (hyperkalemia). Monitor potassium and creatinine within 1 week of starting, then regularly. Avoid if potassium is >5.0 mEq/L or eGFR is <30 mL/min/1.73m² (use with extreme caution if 30–45).

Finerenone (Kerendia): A non-steroidal MRA with a different structure. Originally approved for diabetic kidney disease, it received FDA approval on July 14, 2025 for heart failure with left ventricular ejection fraction of 40% or greater (HFmrEF and HFpEF), based on the FINEARTS-HF trial (2024). Lower hyperkalemia risk than spironolactone/eplerenone. Ask your cardiologist about this option if you have CKD or HFpEF.

SGLT2 inhibitors were originally developed for diabetes but have proven to be transformative heart failure drugs, benefiting patients regardless of EF or diabetes status.

• Dapagliflozin (Farxiga): 10 mg once daily. FDA approved for HFrEF (DAPA-HF trial: 26% reduction in CV death/HF hospitalization) and across all EF types
• Empagliflozin (Jardiance): 10 mg once daily. FDA approved for HFrEF (EMPEROR-Reduced: 25% reduction) and HFpEF (EMPEROR-Preserved: 21% reduction in CV death/HF hospitalization)

How they work: Promote glucose and sodium excretion through the kidneys, reducing fluid overload and protecting both the heart and kidneys through mechanisms that are still being fully understood (improved energy metabolism, reduced inflammation, reduced fibrosis).

Key trials for HFpEF:

• DELIVER (dapagliflozin in HFmrEF/HFpEF): 18% reduction in CV death or worsening HF
• EMPEROR-Preserved (empagliflozin in HFpEF): 21% reduction in CV death or HF hospitalization

Side effects: Genital yeast infections (especially in women and uncircumcised men), urinary tract infections, mild volume depletion. Rare risk of diabetic ketoacidosis (DKA) in patients with diabetes — hold before surgery. Generally very well tolerated.

Why they are often started first: No dose titration needed, once-daily dosing, well tolerated, do not lower blood pressure as much as other pillars, provide kidney protection. Many cardiologists now start SGLT2i as the first GDMT agent.

HFpEF treatment requires a phenotype-specific approach because HFpEF is not one disease — it is a syndrome with multiple underlying causes:

Tirzepatide (Zepbound/Mounjaro) for HFpEF with obesity:

• The SUMMIT trial (2024) randomized 731 patients with HFpEF and BMI ≥30 to tirzepatide vs. placebo
• Results: 38% reduction in composite of cardiovascular death or worsening HF events; mean weight loss of ~13%; significant improvement in Kansas City Cardiomyopathy Questionnaire (KCCQ) symptom scores; improved 6-minute walk distance
• Tirzepatide is a dual GLP-1/GIP receptor agonist (weekly subcutaneous injection)
• Regulatory status: FDA-approved for obesity (Zepbound) and type 2 diabetes (Mounjaro). Lilly withdrew its specific HFpEF FDA application in 2025; however, the SUMMIT data supports off-label use in obese HFpEF patients, and many cardiologists are prescribing it in this setting
• Other GLP-1 RAs (semaglutide, liraglutide) also show promise for HFpEF with obesity (STEP-HFpEF trials with semaglutide showed symptom improvement)

Finerenone (FINEARTS-HF):

• The FINEARTS-HF trial (2024) showed finerenone reduced a composite of total worsening HF events and CV death in patients with HFmrEF and HFpEF (EF ≥40%)
• Dosing: 10–20 mg daily; lower hyperkalemia risk than traditional MRAs
• FDA-approved July 14, 2025 for heart failure with LVEF ≥40% (HFmrEF and HFpEF) — based on FINEARTS-HF. The label now covers both diabetic kidney disease and heart failure.

Diuretics: Loop diuretics (furosemide, bumetanide, torsemide) remain essential for congestion management in all HF types. They treat symptoms but do not change disease progression. Adjust based on weight, symptoms, and kidney function.

If you have been diagnosed with ATTR-CM (transthyretin amyloid cardiomyopathy), specific therapies can slow or stabilize the disease by preventing further amyloid deposition:

TTR stabilizers (prevent the TTR protein from misfolding):

• Tafamidis (Vyndaqel 80 mg daily [four 20 mg capsules] or Vyndamax 61 mg daily): FDA-approved 2019 for ATTR-CM. The ATTR-ACT trial showed a 30% reduction in all-cause mortality and 32% reduction in CV hospitalizations. Standard of care for ATTR-CM. Note: Vyndaqel and Vyndamax are NOT interchangeable on a per-mg basis. Very expensive (~$225,000/year).
• Acoramidis (Attruby, 712 mg twice daily — two 356 mg tablets): FDA-approved November 2024. A next-generation TTR stabilizer that achieves >90% TTR stabilization (compared to ~75% with tafamidis). The ATTRibute-CM trial showed significant reductions in all-cause mortality and CV hospitalizations with acoramidis vs. placebo. May be more effective than tafamidis at preventing misfolding, though no head-to-head trial exists yet.

TTR gene silencers (reduce TTR protein production):

• Patisiran (Onpattro): IV infusion every 3 weeks. Originally approved for hereditary ATTR polyneuropathy; APOLLO-B trial showed cardiac benefit. Reduces TTR production by ~80%.
• Vutrisiran (Amvuttra): Subcutaneous injection every 3 months. Originally approved for hereditary ATTR polyneuropathy; FDA expanded approval to ATTR-CM (cardiomyopathy) in 2025 based on the HELIOS-B trial, which demonstrated significant cardiac benefits including reduced mortality and CV events. Now approved for both wild-type and hereditary ATTR-CM. More convenient dosing than patisiran.
• Eplontersen (Wainua): Monthly subcutaneous injection. Approved for hereditary ATTR with polyneuropathy. Cardiac outcomes data anticipated.

Important: Standard HF medications (diuretics, SGLT2i) are also used in ATTR-CM, but beta-blockers and ARNI must be used with caution — these patients depend on heart rate to maintain cardiac output, and BP may already be low. Digoxin is generally avoided (binds to amyloid fibrils, risk of toxicity).

Iron deficiency is extremely common in heart failure — present in 40–60% of patients — and worsens symptoms, exercise capacity, and outcomes even without anemia. It occurs because of poor absorption, inflammation, and diuretic use.

• Who should be tested: All heart failure patients should have ferritin and TSAT (transferrin saturation) checked. Iron deficiency in HF is defined as ferritin <100 ng/mL, or ferritin 100–299 ng/mL with TSAT <20%.
• Treatment: IV iron (ferric carboxymaltose or ferric derisomaltose) is recommended over oral iron, which is poorly absorbed in HF. Given as a simple infusion in the office or infusion center.
• Evidence: AFFIRM-AHF trial showed 26% reduction in HF hospitalizations with IV ferric carboxymaltose. IRONMAN confirmed benefits with ferric derisomaltose. HEART-FID (ferric carboxymaltose) showed trends toward benefit.
• Guidelines: 2022 AHA/ACC/HFSA gives a Class 2a recommendation for IV iron in HFrEF with iron deficiency.

Ask your cardiologist: “Have my iron levels been checked? Should I receive IV iron?”

Diuretics (loop diuretics):

• Furosemide (Lasix), bumetanide (Bumex), torsemide (Demadex) — used to relieve congestion
• Adjust doses based on daily weights, symptoms, and kidney function
• Torsemide may have advantages over furosemide (more consistent absorption, longer duration)
• Thiazide diuretics (metolazone, chlorthalidone) can be added for diuretic resistance

Hydralazine + Isosorbide dinitrate (BiDil):

• Specifically studied in African American patients with HFrEF (A-HeFT trial: 43% mortality reduction)
• Can be added to standard GDMT or used when ARNI/ACEi/ARB is not tolerated

Vericiguat (Verquvo):

• Soluble guanylate cyclase stimulator for high-risk HFrEF patients after recent decompensation
• VICTORIA trial: modest benefit in reducing CV death/HF hospitalization
• Typically added after all four pillars are optimized in patients with ongoing events

Digoxin:

• Can reduce hospitalizations in HFrEF but does not improve survival
• Useful for heart rate control in atrial fibrillation
• Narrow therapeutic window — levels must be monitored (target 0.5–0.9 ng/mL)

Ivabradine (Corlanor):

• Slows heart rate without lowering blood pressure
• For HFrEF patients in sinus rhythm with HR ≥70 bpm on maximum tolerated beta-blocker
• SHIFT trial: 18% reduction in CV death/HF hospitalization

Starting GDMT is one of the most important things you will do for your heart, but the first few weeks can feel counterintuitive. Understanding what is normal — and what is not — makes the difference between pushing through a temporary adjustment and stopping a medication that is trying to help you.

Beta-blockers (carvedilol, metoprolol succinate): These drugs slow your heart rate and can initially make you feel more tired, slightly breathless, or like your heart failure is worsening. This is a known effect during the first 2–4 weeks of uptitration, not a sign the medication is failing. In clinical trials, patients who felt slightly worse initially went on to have substantial improvements in EF and survival. Your cardiologist will titrate slowly to allow your heart to adapt. Do not stop the medication without calling your team first.

ACE inhibitors, ARBs, and ARNIs (Entresto): The most common side effect is dizziness, especially when you stand from sitting or lying. This happens because these drugs lower blood pressure. Strategies that help: stand up slowly, sit on the edge of the bed for 30 seconds before rising, take the first dose at bedtime. If you develop a persistent dry cough with an ACE inhibitor (this affects 5–20% of patients), your doctor may switch you to an ARB or ARNI, which do not cause cough.

Diuretics (furosemide/Lasix, torsemide, bumetanide): These cause frequent urination, which is the point — they are removing excess fluid from your body. Most patients prefer taking diuretics in the morning so they are not getting up repeatedly at night. If you take a second dose, take it by early afternoon. The first sign that diuretics are working is usually a drop in weight and improved breathlessness within 1–3 days.

MRAs (spironolactone, eplerenone): Can cause elevated potassium, especially in combination with ACE inhibitors. Your doctor will monitor your potassium closely after starting these and after any dose changes. Men may notice breast tenderness or gynecomastia with spironolactone — eplerenone is an alternative with fewer hormonal side effects.

SGLT2 inhibitors (dapagliflozin, empagliflozin): Generally very well tolerated. The main adjustment is slightly increased urination, especially in the first week. Genital hygiene is important to reduce infection risk. Follow the sick-day rules above.

The full optimization process takes 3–6 months. You will start at low doses and gradually titrate up. Labs are checked frequently at first. This is normal. The benefits — including EF recovery — often do not appear until weeks to months after reaching target doses. Many patients feel significantly better by 3–6 months.

Heart failure management requires regular blood tests. Understanding what is being measured and why helps you feel less like a passive patient and more like an active partner in your care.

Comprehensive metabolic panel (CMP) — creatinine, potassium, sodium, BUN:

• Creatinine: A measure of kidney function. ACE inhibitors, ARBs, and ARNIs reduce blood flow to the kidneys slightly, which raises creatinine a small amount. A rise of up to 25–30% from your baseline is usually acceptable and expected. If it rises sharply, your team may lower the dose or add bridging care.
• Potassium: ACE inhibitors, ARBs, ARNIs, and MRAs all raise potassium. Normal is 3.5–5.0. Above 5.5 should prompt a call to your cardiologist. Above 6.0 is potentially dangerous. If potassium runs high chronically, your doctor may prescribe a potassium binder (patiromer or sodium zirconium cyclosilicate) that lets you continue your heart medications.
• Sodium: Low sodium (hyponatremia) often indicates fluid overload or high diuretic doses. It is associated with worse prognosis and may prompt adjustment in fluid restriction or diuretic dosing.

NT-proBNP or BNP: The biomarker that measures how hard your heart is straining. Higher values mean more wall stress and worse outcomes; lower values mean treatment is working. At diagnosis, your level may be very elevated. As your treatment is optimized, it should fall — and a meaningful drop is a sign your heart is recovering. Your team may target a specific number. You should know yours.

How often will you need blood tests?

• After any new medication or dose change: 1–2 weeks
• During active titration: Monthly
• When stable on target doses: Every 3–6 months
• After hospitalization or illness: 1–2 weeks

Keep a personal copy of your latest labs with reference ranges. Ask your cardiologist what numbers to watch and what to do if one is out of range before your next scheduled visit.

GDMT for heart failure can cost $400–800 per month without insurance coverage. SGLT2 inhibitors and ARNIs (Entresto) are among the most expensive and also among the most impactful. Cost should never force you to choose between essential medications, because help exists.

Generic vs. brand-name options:

• Most legacy heart failure drugs are inexpensive generics: lisinopril, enalapril, carvedilol, metoprolol succinate, spironolactone, furosemide, torsemide, eplerenone — all cost $4–$15/month at most pharmacies
• ARNIs (sacubitril/valsartan, branded as Entresto): brand-only in the US as of 2024. A generic version became available in late 2025 through an authorized generic agreement. Ask your pharmacist about the current availability and price.
• SGLT2 inhibitors (dapagliflozin/Farxiga, empagliflozin/Jardiance): still brand-name. Patient assistance and copay cards can bring costs to $0 or near-zero.

Manufacturer assistance programs:

• AstraZeneca (dapagliflozin/Farxiga): AZ&Me Prescription Savings Program — may be free or low-cost for qualifying patients without insurance
• Boehringer Ingelheim / Lilly (empagliflozin/Jardiance): Jardiance Savings Card — eligible commercially insured patients often pay $10/month
• Novartis (Entresto): Entresto Copay Card; Novartis Patient Assistance Foundation for uninsured patients

Other resources:

• NeedyMeds.org: Searchable database of patient assistance programs for every drug
• RxAssist.org: Lists manufacturer programs and enrollment instructions
• GoodRx: Free coupons that often beat insurance prices for generics; compare prices across pharmacies
• Medicare Low-Income Subsidy (Extra Help): If you have Medicare Part D and limited income, you may pay $0–$4 per generic drug and very low amounts for brand-name drugs. Apply through SSA.gov or call 1-800-772-1213
• Your HF clinic social worker: Ask to be connected — they navigate insurance issues and assistance programs every day

Never stop a medication because of cost without first telling your cardiologist. There is almost always an alternative approach, and stopping suddenly can cause rapid deterioration.

The most dangerous period for heart failure patients is the 30–90 days after a hospitalization. Most readmissions are preventable. A written action plan — tailored to your specific situation — is the single most important tool for staying out of hospital.

The three-zone action plan (ask your cardiologist to create yours):

GREEN ZONE — All clear. Your baseline weight, no new symptoms, sleeping flat, activity tolerance is your normal. Continue all medications as prescribed. Weigh yourself every morning.

YELLOW ZONE — Caution, take action. Any of the following: weight gain >2 pounds in one day, or >5 pounds over one week; increased ankle or leg swelling; shortness of breath with less activity than usual; needing to add a pillow to sleep; coughing more at night; reduced urine output. Action: adjust your diuretic as per your written plan (e.g., “take an extra 20 mg furosemide”), and call your HF nurse or clinic within 24 hours.

RED ZONE — Get help now. Any of the following: shortness of breath at rest or waking you from sleep; chest pain or pressure; sudden severe swelling; coughing up pink or foamy fluid; fainting or near-fainting; confusion. Action: call 911 or go to the emergency room. Do not wait.

Other warning signs to report promptly:

• Dizziness when standing (could indicate your blood pressure is too low from medications)
• Heart pounding, racing, or skipping beats lasting more than a few minutes
• Inability to take your medications due to vomiting or severe illness
• Fever >101°F with worsening symptoms (infection can trigger decompensation)

Keep a daily weight log visible on your fridge. Take it to every appointment. Your team wants to see the trend, not just a single number. Smart scales that send weight directly to your care team’s system are increasingly available through clinic remote monitoring programs — ask if yours offers this.

Daily weights: Weigh yourself every morning, after urinating, before eating, in similar clothing, on the same scale. Record the number.

• A gain of >2 pounds in one day or >5 pounds in one week usually means fluid retention
• Contact your doctor or follow your “action plan” for diuretic adjustment
• Sudden weight loss may indicate dehydration (especially in hot weather or with illness)

Symptom tracking: Note daily: breathlessness level (with activity, at rest, lying flat), ankle swelling, energy level, appetite, and number of pillows needed to sleep. A symptom diary helps identify early decompensation.

Blood pressure and heart rate: Check and record at least twice weekly, or daily if on medication titration.

Sodium (salt) causes your body to retain water, worsening congestion and swelling. While the exact optimal sodium level is debated (the SODIUM-HF trial showed mixed results with very strict restriction), most guidelines recommend:

• General target: Less than 2,000–2,300 mg of sodium per day (about 1 teaspoon of salt)
• Where sodium hides: Restaurant meals, processed foods, canned soups, deli meats, bread, condiments, and fast food are the biggest sources — not the salt shaker
• Practical tips: Cook at home more often, read nutrition labels (check mg of sodium per serving), use herbs and spices instead of salt, rinse canned vegetables, choose “low-sodium” options
• Fluid restriction: Usually 1.5–2 liters per day for patients with severe HF or recurrent fluid overload. Includes all liquids: water, coffee, soup, ice cream, etc.

Heart-healthy diet: Emphasize fruits, vegetables, whole grains, lean protein, and healthy fats. The DASH (Dietary Approaches to Stop Hypertension) and Mediterranean diets are recommended. Limit alcohol (can worsen HF; avoid completely if alcoholic cardiomyopathy). Maintain a healthy weight — both obesity and unintentional weight loss (cardiac cachexia) are concerning.

Exercise is safe and beneficial for most heart failure patients. The HF-ACTION trial showed that regular exercise improves symptoms, quality of life, and reduces hospitalizations.

• Cardiac rehabilitation: A structured, supervised exercise program (typically 36 sessions over 12 weeks) with education on diet, medications, and self-management. Covered by Medicare and most insurance for HF with a recent hospitalization or stable symptomatic HF.
• General recommendation: 150 minutes per week of moderate-intensity aerobic activity (walking, cycling, swimming) as tolerated
• Start gradually: If deconditioned, begin with 5–10 minutes of walking and increase slowly
• Warning signs during exercise: Stop and rest if you experience chest pain, severe breathlessness disproportionate to effort, dizziness, or an ICD shock. Report these to your cardiologist.
• Resistance training: Light resistance exercises are safe and improve muscle strength, which helps daily functioning

Ask your doctor for a cardiac rehabilitation referral — it is one of the most effective interventions available but is dramatically underutilized (only ~10% of eligible patients participate).

Depression affects 20–40% of heart failure patients — far more than the general population. It worsens outcomes, reduces medication adherence, and diminishes quality of life. Anxiety is also common, especially fear of device shocks (in ICD patients) and fear of disease progression.

• Screening: Your HF team should screen for depression and anxiety at each visit. The PHQ-9 is a standard screening tool.
• Treatment: SSRIs (sertraline, escitalopram) are generally safe in HF. Avoid TCAs (tricyclic antidepressants) due to cardiac risks. Cognitive behavioral therapy (CBT) is effective.
• Cognitive changes: Heart failure can affect memory and thinking ability, especially during decompensation. This is partly due to reduced blood flow to the brain. Report cognitive concerns to your doctor.
• Caregiver burnout: Caregivers of HF patients have high rates of depression and anxiety themselves. Seek support through caregiver groups, respite care, and counseling.

Heart failure rarely exists alone. Managing coexisting conditions is essential:

• Atrial fibrillation (AFib): Present in 30–50% of HF patients. Rate control with beta-blockers; rhythm control with amiodarone or catheter ablation may improve outcomes in HFrEF (CASTLE-AF trial). Anticoagulation is essential to prevent stroke.
• Chronic kidney disease (CKD): Very common in HF and affects medication dosing. SGLT2 inhibitors protect both heart and kidneys. Finerenone has dual cardiorenal benefits. Monitor creatinine and potassium closely.
• Diabetes: SGLT2 inhibitors serve double duty (HF + diabetes). Metformin is safe in stable HF. Avoid thiazolidinediones (pioglitazone, rosiglitazone — they worsen fluid retention).
• Sleep-disordered breathing: Central sleep apnea and obstructive sleep apnea are very common in HF. Obstructive sleep apnea should be treated with CPAP. SERVE-HF showed that adaptive servo-ventilation (ASV) is harmful in HFrEF with central sleep apnea — avoid.
• Iron deficiency: Check ferritin and TSAT in all HF patients; treat with IV iron if deficient (see Treatment section).
• Gout: Common due to diuretic use and reduced kidney function. Allopurinol and febuxostat are safe for prevention. Avoid NSAIDs (ibuprofen, naproxen) — they worsen HF and kidney function.

Infections are a common trigger for HF decompensation. Stay up to date with:

• Annual influenza vaccine
• Pneumococcal vaccines (PCV20 or PCV15 followed by PPSV23)
• COVID-19 vaccines (updated boosters as recommended)
• RSV vaccine (for adults ≥60)

Respiratory infections can precipitate acute decompensation. Seek early medical attention for fevers, worsening cough, or breathing changes during cold and flu season.

Heart failure is not one condition — it is a syndrome with two main subtypes that have different causes, different treatments, and a somewhat different experience in daily life. Knowing which type you have helps you understand why your treatment plan looks the way it does.

HFrEF (ejection fraction ≤40%) — “weak pumping heart.” The left ventricle is enlarged and does not squeeze as forcefully as it should. This type responds well to GDMT — the four-pillar medication strategy described above. Most medications shown to reduce hospitalizations and prolong life were studied in HFrEF. EF can recover substantially with treatment. Activity intolerance, fatigue, and exercise breathlessness are the dominant daily symptoms.

HFpEF (ejection fraction ≥50%) — “stiff heart.” The heart squeezes normally but is too stiff to relax properly and fill with blood. This type is more common in women, in people with obesity, diabetes, hypertension, and atrial fibrillation. SGLT2 inhibitors are now proven to reduce hospitalizations in HFpEF (EMPEROR-Preserved and DELIVER trials). GLP-1 agonists (semaglutide) reduce symptoms in obese HFpEF patients. Daily symptoms are often most prominent with exertion and may be accompanied by heavy legs and breathlessness with ordinary activities.

What this means in daily life:

• In HFrEF, the goal is aggressive GDMT titration and EF recovery. Activity should be encouraged (cardiac rehab); the heart remodels better with exercise stimulus.
• In HFpEF, controlling co-conditions is central: get blood pressure to target, treat sleep apnea, manage weight if overweight. These are not optional extras — they are the core therapy.
• Both types: low sodium intake, daily weights, fluid awareness, and prompt reporting of decompensation signs apply equally.
• HFmrEF (EF 41–49%) is treated similarly to HFrEF; many trials now show benefit from the same four-pillar GDMT.

Ask your doctor: “Which subtype do I have, and what does that mean for which medications will help me most?”

Sexual activity is a topic many heart failure patients hesitate to raise, and many clinicians forget to address. It matters to quality of life and deserves an honest conversation with your care team.

Is sex safe with heart failure? For most stable patients with NYHA Class I–II (able to walk several blocks or climb stairs without severe symptoms), sexual activity is safe. The cardiovascular demand of sex with a familiar partner is roughly equivalent to walking up two flights of stairs — a standard functional test. If you can do that without significant symptoms, sex is generally safe at a similar level of exertion.

When to be more cautious:

• NYHA Class III–IV: discuss with your cardiologist before resuming. A formal exercise tolerance test or cardiac rehabilitation assessment can help define a safe activity level.
• Recent hospitalization: wait until you have been medically stable at home for at least 2–4 weeks, or until your cardiologist clears you.
• Significant symptoms during light activities: this suggests your heart failure is not yet well-controlled. Optimizing medical therapy first will likely also improve sexual function.

Medications and sexual function: Some heart failure medications can affect sexual function. Beta-blockers can reduce libido and, in men, cause erectile dysfunction in a minority of patients. ACE inhibitors and ARBs have neutral or positive effects on erectile function. If you are experiencing sexual dysfunction and feel it may be related to your medications, raise it with your cardiologist — there is often an alternative. PDE5 inhibitors (sildenafil, tadalafil) are contraindicated with nitrates but are generally safe and may actually be beneficial in HFpEF; do not use them without discussing with your cardiologist first.

The emotional dimension: Heart failure affects body image, energy, and confidence. Both partners may be afraid — of triggering symptoms, of the device firing, of the unknown. Opening the conversation, possibly with help from a cardiac psychologist or your clinic’s social worker, is just as important as the physical safety question.

Heart failure does not have to ground you. With careful planning, most patients can travel, drive, and participate in the activities they love.

Air travel: Flying is safe for most stable heart failure patients. Key considerations:

• Fluid shifts: The low cabin humidity and prolonged sitting promote fluid retention and leg swelling. Wear compression stockings, walk the aisle every 1–2 hours, and stay hydrated (water, not alcohol).
• High altitudes: Cabin pressure is typically equivalent to 6,000–8,000 feet. This reduces oxygen availability slightly. Most stable patients tolerate this well, but if you have severe HF or significant oxygen requirements, discuss supplemental O2 needs with your cardiologist in advance.
• Medications on flights: Carry all medications in your carry-on bag. Bring enough for the trip plus several extra days. If you are crossing time zones, ask your pharmacist or cardiologist how to adjust timing-sensitive medications.
• Medical care access: Get travel insurance that covers cardiac emergencies. Identify hospitals near your destination.

Driving: Most heart failure patients can continue driving safely. Exceptions:

• If you have an ICD, most states require a driving-restriction period (typically 6 months after a defibrillator firing; varies by state and reason for firing). Your electrophysiologist will advise you.
• If you experience syncope (fainting), dizziness, or other symptoms that could impair driving, do not drive until cleared by your physician.
• LVAD patients typically cannot drive (device restrictions vary by manufacturer).

Staying active: Physical inactivity is harmful in heart failure. Cardiac rehabilitation and supervised exercise are strongly encouraged. For daily life:

• Moderate exercise (walking, swimming, cycling) is beneficial — not dangerous — for stable HF
• Stop and rest if you develop chest pain, severe breathlessness, lightheadedness, or palpitations
• Avoid very hot or very cold environments, which stress the cardiovascular system
• Listen to your body: on bad days, reduce intensity; on good days, stay within your plan’s guidelines

One of the most effective things you can do to prevent hospitalization is act early when your weight rises. Most patients who end up admitted for decompensated heart failure had warning signs 3–7 days before admission that, in retrospect, were not acted on quickly enough. Here is exactly what to do.

Step 1: Confirm the weight gain is real. Weigh yourself again the next morning, same conditions (post-void, pre-breakfast, same scale, similar clothing). A single high number can result from eating a large meal or weighing at a different time. Two consecutive high mornings is more reliable signal.

Step 2: Check for other symptoms. Are your ankles or legs more swollen than usual? Are you more breathless with activities that used to be easy? Are you waking up at night with breathlessness, or needing to prop up with extra pillows? These symptoms alongside weight gain mean act now, not wait and see.

Step 3: Follow your written action plan. Your cardiologist should have given you a flexible diuretic plan — for example: “If weight up >3 lbs, take an extra 20 mg furosemide and call the clinic.” Follow it exactly. If you do not have a written plan, call your clinic today and ask for one.

Step 4: Call your HF clinic or nurse line. Do not wait for your next scheduled appointment if you are in the yellow zone. Most advanced HF programs have a nurse line for exactly this situation. A phone call can often avert a hospitalization — the nurse can authorize a diuretic dose adjustment, order labs, or schedule an urgent visit, depending on your situation.

Step 5: Restrict sodium temporarily. On a high-weight day, aim for the strictest interpretation of your sodium limit (toward 1,500–2,000 mg rather than your usual 2,000–2,500 mg). Read food labels carefully; restaurant food, canned soups, and deli meats are the most common sodium traps.

Step 6: Document what happened and what you did. Note the dates, the weight readings, the symptoms, and the actions you took. Bring this log to your next appointment. This data helps your team understand your fluid behavior and refine your plan for next time.

When to skip the steps and go straight to the ER: If you have red-zone symptoms (breathlessness at rest, chest pain, pink foamy cough, fainting), do not call the clinic first. Call 911 or go immediately to the emergency department.

Cardiac rehabilitation is one of the most underutilized tools in heart failure care. Studies consistently show that patients who complete a cardiac rehab program have lower rates of hospitalization, better functional capacity, and improved quality of life — yet fewer than 15% of eligible heart failure patients enroll.

What cardiac rehab involves: A medically supervised program of graded exercise (typically on treadmills, exercise bikes, or rowers), education about heart failure management, dietary counseling, and psychosocial support. Most programs run 2–3 sessions per week for 12 weeks. Sessions last about 1 hour. Your heart rate, blood pressure, and rhythm are monitored throughout.

Who it is for: Cardiac rehab is covered by Medicare and most insurance plans for patients with stable symptomatic heart failure (NYHA Class II–III), particularly those with HFrEF. You need a physician referral. If you were recently hospitalized for heart failure or had a cardiac procedure, you are almost certainly eligible. Ask for a referral at your next visit if you have not been offered one.

What to expect:

• Week 1–2: Baseline testing and very light exercise. The team learns your tolerance and watches for abnormal responses. This may feel almost too easy — that is intentional.
• Week 3–8: Progressive increase in intensity. Most patients notice meaningful improvement in how far they can walk and how breathless they feel at a given pace.
• Week 9–12: Higher intensity work toward your individual target; transition planning for home exercise maintenance after the program ends.

Home-based cardiac rehab: Some programs offer a supervised home option, where equipment is provided and a health coach calls or video-checks in during sessions. This is especially valuable for patients with transportation barriers or living far from a rehab center. Ask your cardiologist if a home-based program is available in your area.

After cardiac rehab: The benefits only last if you keep exercising. At program completion, you will receive a personalized home exercise plan. Maintenance sessions at a community gym or through a heart failure exercise class can help sustain the gains. The American Heart Association’s HeartSelect tool at heart.org can help you locate programs near you.

Dietary management in heart failure is one of the most important — and most misunderstood — aspects of living with the condition. The rules are nuanced, and getting them wrong in either direction (too much sodium, but also too little fluid restriction) can cause problems.

Sodium: The standard recommendation is to limit sodium to 2,000–2,500 mg per day for most heart failure patients. Sodium causes the body to retain fluid, which increases the workload on a failing heart. The biggest sources of sodium in the American diet are not the salt shaker — they are packaged, processed, canned, and restaurant foods.

Practical sodium targets:

• Canned soups: Often contain 700–900 mg per serving. Look for “no salt added” or low-sodium versions (<140 mg per serving).
• Deli meats and cold cuts: 400–600 mg per 2 oz serving. Opt for fresh-cooked lean protein instead.
• Bread: 100–200 mg per slice — adds up quickly. Check labels.
• Restaurant meals: Typically 1,500–3,000 mg per entree. Ask for sauces on the side; avoid dishes described as “brined,” “cured,” or “smoked.”
• Condiments: Soy sauce (900 mg/tbsp), ketchup (150 mg/tbsp), and pickles are high. Look for reduced-sodium versions.

Fluid restriction: Not all heart failure patients need strict fluid restriction. The current evidence suggests that 2,000 mL (about 67 oz or 8 cups) per day is an appropriate limit for most patients with moderate-to-severe HF. However, over-restricting fluids can cause dehydration and worsen kidney function, especially in hot weather, during illness, or for patients on high-dose diuretics. Your cardiologist should specify your individual target.

Potassium: This is where dietary advice for heart failure diverges from other conditions. Many patients are told to eat high-potassium foods (bananas, oranges, potatoes) to prevent hypokalemia. However, if you are on ACE inhibitors, ARBs, ARNIs, or MRAs — which all raise potassium — you may need to moderate your potassium intake instead. Ask your cardiologist specifically: “Should I be eating more potassium or avoiding excess potassium?” The answer depends on your labs and medications.

Alcohol: Alcohol is directly toxic to heart muscle and can worsen heart failure in any quantity. The ACC/AHA guidelines recommend abstinence for all patients with alcohol-related cardiomyopathy, and significant restriction (no more than 1 drink occasionally) for those with other forms of HF. If alcohol is contributing to your heart failure, stopping completely is one of the most powerful interventions available — EF recovery has been documented even with significant disease.

Implantable Cardioverter-Defibrillator (ICD):

• Prevents sudden cardiac death from dangerous heart rhythms (ventricular tachycardia/fibrillation)
• Primary prevention: Recommended for HFrEF with EF ≤35% despite ≥3 months of optimal GDMT, NYHA II–III, and expected survival >1 year
• Continuously monitors heart rhythm; delivers a shock if life-threatening arrhythmia detected
• Subcutaneous ICD (S-ICD) available for patients who don’t need pacing

Cardiac Resynchronization Therapy (CRT):

• A specialized pacemaker that coordinates the beating of both sides of the heart (left and right ventricles)
• Indications: HFrEF with EF ≤35%, NYHA II–IV (ambulatory), sinus rhythm, LBBB with QRS ≥150 ms (strongest indication). Some benefit with non-LBBB or QRS 120–149 ms (weaker evidence).
• Can be combined with ICD (CRT-D) or standalone pacemaker (CRT-P)
• About 60–70% of patients respond to CRT; ~30% are “super-responders” with major EF improvement

Conduction System Pacing (CSP) / Left Bundle Branch Area Pacing (LBBAP):

• A newer pacing approach that stimulates the natural conduction system rather than pacing directly from the muscle
• May provide CRT-like benefits with a simpler implant procedure
• Growing evidence but not yet in all guidelines as a first-line alternative to traditional CRT

Critical point: GDMT must be optimized before device decisions are finalized. Many patients’ EF improves with medications alone, potentially changing device candidacy. Reassess EF after at least 3 months of optimized GDMT.

An LVAD is a mechanical pump surgically implanted to help the weakened left ventricle pump blood. It is used for:

• Bridge to transplant (BTT): Supporting the patient while waiting for a donor heart
• Destination therapy (DT): Long-term support for patients who are not transplant candidates
• Bridge to candidacy: Improving organ function to make a patient eligible for transplant

Who is considered: Patients with advanced HFrEF (INTERMACS profiles 1–4) who remain symptomatic despite optimal GDMT. INTERMACS profiles range from 1 (cardiogenic shock) to 7 (advanced NYHA III symptoms).

What to expect:

• Major open-heart surgery with significant recovery period
• An external battery pack and controller must be worn at all times (connected via a driveline exiting the skin)
• Requires lifelong anticoagulation (warfarin)
• Complications include bleeding, driveline infections, stroke, pump thrombosis, and right heart failure
• 2-year survival with current devices (HeartMate 3): approximately 75–80% for DT; higher for BTT
• Quality of life and exercise capacity improve dramatically for most recipients

Heart transplant remains the definitive treatment for end-stage heart failure, offering the potential for near-normal life expectancy and quality of life.

• Survival: Median survival after heart transplant is approximately 12–14 years; 1-year survival ~90%, 5-year ~80%
• When to refer: Consider referral when HF is advanced (NYHA III–IV) despite optimized therapy, repeated hospitalizations, declining functional status, or need for inotrope support. Refer early — evaluation takes months.
• Evaluation: Comprehensive assessment including right heart catheterization, psychosocial evaluation, infection screening, cancer screening, and assessment of other organ function
• After transplant: Lifelong immunosuppression medications (tacrolimus, mycophenolate, prednisone initially), frequent biopsy surveillance for rejection, increased infection and cancer risk, regular clinic visits
• Allocation: UNOS allocation system with status tiers; average wait time varies by region and blood type

Donation after circulatory death (DCD) hearts: Expanding the donor pool. Combined with ex vivo heart perfusion (OCS Heart, SherpaPak), enabling use of hearts previously considered unusable.

Acute decompensation — a sudden worsening requiring hospitalization — is a dangerous event. Each hospitalization carries significant mortality risk and accelerates disease progression.

• IV diuretics: High-dose IV furosemide (often 2.5× the home oral dose) is the mainstay. Goal: relieve congestion (weight loss, symptom improvement, reduced NT-proBNP).
• Monitoring: Daily weights, strict intake/output, electrolytes (especially potassium, magnesium), kidney function, ongoing symptom assessment.
• IV vasodilators: Nitroglycerin or nitroprusside for severe hypertension with pulmonary edema.
• Inotropes: Dobutamine or milrinone for cardiogenic shock or critically low cardiac output. Used short-term; long-term inotropes are reserved for palliative care or bridge to transplant/LVAD.
• Do not stop GDMT during hospitalization unless there is cardiogenic shock or severe hypotension. Evidence supports continuing beta-blockers (at reduced dose if needed) through most hospitalizations.
• Before discharge: Medications should be optimized, a follow-up appointment within 7 days arranged, diuretic plan clarified, and patient/caregiver education reinforced.

The heart failure pipeline is among the most active in medicine. Emerging therapies include:

• Omecamtiv mecarbil: A cardiac myosin activator that strengthens heart contractions without increasing energy demand. GALACTIC-HF (NCT02929329) showed an 8% reduction in CV death/HF events in HFrEF. FDA declined approval in 2023 (Complete Response Letter), requesting additional data; not currently available for clinical use.
• Ziltivekimab (anti-IL-6): HERMES trial (NCT05636176, Phase 3, ongoing) targeting residual inflammation in HFpEF/HFmrEF. Anti-inflammatory approach to a condition driven partly by chronic inflammation. Results pending.
• Digitoxin revival: DIG-AF and related studies are re-evaluating cardiac glycosides for HF with atrial fibrillation. Digitoxin has more predictable pharmacokinetics than digoxin.
• NTLA-2001 (CRISPR gene editing): A one-time treatment that permanently edits the TTR gene to stop amyloid production in hereditary ATTR. Phase 1 data (NCT04601051) showed >90% sustained reduction in TTR levels. Now in Phase 3 MAGNITUDE trial (NCT06128629). Revolutionary potential for a single-dose cure.
• Mavacamten and aficamten: Cardiac myosin inhibitors for hypertrophic cardiomyopathy (HCM)-related HF. Already approved for obstructive HCM.
• Transcatheter mitral valve repair (TEER/MitraClip): For patients with HFrEF and severe leaking of the mitral valve (functional mitral regurgitation), a minimally invasive clip procedure can reduce the leak and improve symptoms. The COAPT trial (NCT01626079) showed reduced HF hospitalizations and improved survival in carefully selected patients. Ask your cardiologist if you might be a candidate.
• Next-generation LVADs: Fully implantable devices with wireless charging (eliminating the driveline infection risk) are in development.
• CardioMEMS (remote PA pressure monitoring): An implantable sensor in the pulmonary artery that transmits daily pressure readings to your doctor, allowing proactive medication adjustments. CHAMPION trial (NCT00531661) showed 37% reduction in HF hospitalizations.

Ask your cardiologist about clinical trials at every visit. ClinicalTrials.gov lists all active studies.

Palliative care is appropriate at any stage of heart failure — it is not just for end of life. It focuses on symptom relief, quality of life, and supporting patients and families through difficult decisions.

• When to involve palliative care: NYHA III–IV symptoms, frequent hospitalizations, declining function despite optimal therapy, complex symptom management needs, difficult decisions about devices/transplant/LVADs
• Advance directives: Designate a healthcare power of attorney. Document preferences for CPR, mechanical ventilation, ICD shocks (deactivation is common in end-of-life care), and LVAD deactivation.
• Hospice: For patients with estimated prognosis of ≤6 months. Provides comfort-focused care at home or in a hospice facility. ICD deactivation is typically part of the transition.
• Symptom management: Low-dose opioids (morphine) can safely relieve refractory breathlessness. Diuretics continue for comfort. IV inotropes can be used palliatively for symptom relief.

Having these conversations early, while the patient can participate, is a gift to the whole family.

An implantable cardioverter-defibrillator (ICD) is implanted to prevent sudden cardiac death from dangerous heart rhythms. For many patients, receiving an ICD is emotionally complex: relief at having protection, mixed with anxiety about a device that can deliver a shock to the heart. Both feelings are completely normal.

The implantation procedure: An ICD is placed under local anesthesia with sedation, typically as a same-day or overnight procedure. One or more leads (thin wires) are threaded through a vein into the heart. Most patients go home the next day. The device sits just below the collarbone, creating a visible bump under the skin. There is a small incision scar.

What a shock feels like: Most patients who receive a shock describe it as a sudden, forceful thump in the chest — startling and sometimes painful, but over in an instant. About half of ICD shocks occur while the patient is asleep or in a low-activity state. The shock itself is not dangerous; it is the rhythm it is treating that is dangerous. If you receive a shock and feel well afterward, call your electrophysiologist or after-hours line to report it. If you feel unwell, or receive multiple shocks in a short period, call 911.

Avoiding unnecessary shocks: ICDs are programmed conservatively to reduce inappropriate shocks (shocks from fast but non-dangerous rhythms). High heart rates during exercise can occasionally trigger inappropriate therapy. Your device can be reprogrammed if this is occurring. Never try to avoid all physical activity out of fear of the device — deconditioning is harmful.

Electromagnetic interference: Modern ICDs are well-shielded. Ordinary household appliances, computers, and cell phones do not interfere with them (keep your phone on the opposite side from your device). Metal detectors at airports will set off the alarm — carry your device identification card and ask for a hand wand instead. MRI compatibility depends on your specific device — ask your electrophysiologist.

Psychological adjustment: Device anxiety is common and can become debilitating. If fear of shocks is preventing you from sleeping, leaving the house, or engaging in activities, ask for a referral to a cardiac psychologist or a device support group. Many people find that meeting others living well with an ICD is the most powerful reassurance available.

A left ventricular assist device (LVAD) is a surgically implanted mechanical pump that takes over the pumping function of the left ventricle. For patients with end-stage heart failure, it can be life-saving. It is also a major, life-altering decision with significant implications for daily life, and it deserves careful thought and honest discussion.

Why an LVAD might be offered to you:

• Bridge to transplant: You are a transplant candidate but the wait time is long; the LVAD keeps you alive and in better condition while waiting for a donor heart
• Destination therapy: You are not a transplant candidate (due to age, other medical conditions, or personal preference) and the LVAD is intended as long-term, permanent support
• Bridge to recovery or decision: Used temporarily while evaluating reversibility of the heart failure or deciding on long-term strategy

What LVAD life involves:

• A driveline exits through the skin of the abdomen and connects to a controller and batteries worn in a vest or bag at all times — 24 hours a day, 7 days a week
• Showering requires a special waterproof cover over the driveline exit site; swimming is generally not allowed
• You will need a caregiver who is trained in LVAD management at home, including how to respond to device alarms, perform driveline dressing changes, and manage emergencies
• Driveline site infections are the most common serious complication; meticulous hygiene and daily care are required
• Stroke is a significant risk, and lifelong anticoagulation with warfarin is required
• Most patients experience significant improvement in symptoms and exercise capacity, often within weeks of implantation

Questions to ask before deciding: Who will be my primary caregiver and are they able and willing to take on this role? What happens if I decide I no longer want LVAD support? What does deactivation involve and who decides? Is transplant still a possibility for me, or is this destination therapy? What does the data show for LVAD patients with my profile (age, renal function, right heart function)?

Your advanced heart failure team and palliative care team should both be involved in this discussion. Take the time you need. This is a decision that deserves unhurried, honest conversation.

Peripartum cardiomyopathy (PPCM) is a form of heart failure that develops in the last month of pregnancy or within 5 months of delivery in women who had no prior heart disease. It is rare (approximately 1 in 2,000 deliveries in the US, higher in African American women) but serious, and it requires urgent recognition and treatment.

How it presents: The symptoms of PPCM — breathlessness, leg swelling, fatigue, difficulty lying flat — can overlap with normal pregnancy symptoms, which leads to delayed diagnosis. Any new or worsening breathlessness in late pregnancy or shortly after delivery should prompt evaluation. Echocardiography showing reduced EF confirms the diagnosis.

Treatment of PPCM: Once diagnosed, treatment follows GDMT principles, with important medication restrictions. ACE inhibitors, ARBs, and ARNIs are contraindicated during pregnancy but can be started immediately after delivery. Beta-blockers and diuretics can be used in pregnancy. Bromocriptine — a prolactin inhibitor — is used in some centers in addition to standard GDMT and may improve recovery, though it prevents breastfeeding.

Prognosis and recovery: PPCM has a better prognosis than other causes of heart failure. About 50–70% of women recover normal or near-normal EF within 6–12 months with appropriate treatment. Recovery is more likely with earlier diagnosis, early treatment, and higher initial EF. Women who do not recover fully by 6 months are less likely to recover later.

Future pregnancy after PPCM: Subsequent pregnancy carries significant risk, even in women whose EF has fully recovered. There is an approximately 20–30% chance of relapse with the next pregnancy. The risk is substantially higher if EF has not fully recovered. This decision requires detailed counseling with your cardiologist and a maternal-fetal medicine specialist, ideally before conception.

If you or someone you know develops unexplained breathlessness or heart failure symptoms around the time of delivery, request urgent cardiac evaluation. Early treatment dramatically improves outcomes.

Heart failure is one of the conditions where advance care planning — deciding in advance what kinds of care you do and do not want — matters most. It is not a conversation about giving up. It is a conversation about making sure your values guide your care, even if you cannot speak for yourself at a critical moment.

Why heart failure makes this particularly important: The course of heart failure is unpredictable. People can be doing reasonably well and then deteriorate rapidly during a hospitalization. If an ICD or LVAD is involved, there are specific questions about deactivation that need to be addressed before a crisis. Families who have not discussed these matters are often forced to make agonizing decisions under extreme time pressure, without knowing what their loved one would have wanted.

What advance care planning involves:

• Healthcare power of attorney (healthcare proxy / HCPOA): Designate the person you trust most to make medical decisions on your behalf if you are unable to do so. Make sure they know your values, not just the legal document.
• Advance directive / living will: Document your preferences for CPR, mechanical ventilation, feeding tubes, and other specific interventions if you are terminally ill or in a persistent vegetative state.
• POLST / MOLST: A physician-signed order (Physician/Medical Orders for Life-Sustaining Treatment) that is legally actionable in emergency settings. Different from an advance directive, which is an instruction document. Ask your cardiologist if POLST is appropriate for your stage of illness.
• ICD deactivation: An ICD can be turned off when the burdens outweigh the benefits — at end of life, in hospice, or when a patient no longer wants it active. This is legal, ethical, and widely practiced. It does not cause death; it simply removes the device’s intervention if a fatal rhythm occurs. Discuss your preferences about deactivation in advance, so that this decision is made on your terms.

How to start the conversation with your family: Choose a calm moment, not a crisis. You might begin: “I want to talk about what I would want if something happened to my heart and I couldn’t speak for myself. I’m not planning for something bad to happen — I want to make sure that if it does, things go the way I want.” Your HF clinic social worker or palliative care team can facilitate a family meeting if you want support.

• University of Utah Health Heart Failure and Transplant Program: Comprehensive advanced HF center offering LVAD implantation, heart transplant, and multidisciplinary HF care. Referral: (801) 585-7676
• University of Utah Amyloidosis Program: Multidisciplinary clinic for ATTR-CM and AL amyloidosis diagnosis and management, including bone scintigraphy interpretation and TTR stabilizer therapy
• Intermountain Health Heart Failure Clinics: Multiple locations across the Wasatch Front offering GDMT optimization, remote monitoring programs, and cardiac rehabilitation. Locations include Intermountain Medical Center, Utah Valley Hospital, and McKay-Dee Hospital
• Cardiac rehabilitation programs: Available at University of Utah Health, Intermountain Health facilities, and community centers throughout Utah. Ask your cardiologist for a referral.
• American Heart Association — Utah chapter: Support groups, educational events, Go Red for Women campaign. heart.org

• American Heart Association (AHA): heart.org/heart-failure — Patient education, support groups, research funding
• Heart Failure Society of America (HFSA): hfsa.org — Patient resources, HF educational materials
• Amyloidosis Foundation: amyloidosis.org — For ATTR-CM and AL amyloidosis patients and families
• Amyloidosis Research Consortium (ARC): arci.org — Research and advocacy
• Mended Hearts: mendedhearts.org — Peer support for heart disease patients
• WomenHeart: womenheart.org — For women with heart disease
• ClinicalTrials.gov: clinicaltrials.gov — Search for active HF trials near you

• Europe: The 2023 ESC Focused Update integrates SGLT2 inhibitors as Class I across the EF spectrum. Tafamidis is approved for ATTR-CM but acoramidis access varies by country. Finerenone received its US FDA heart-failure indication (LVEF ≥40%) in July 2025; its HF indication remains under EMA review in Europe. CRT guidelines align with AHA but conduction system pacing adoption differs.
• Japan: High prevalence of HFpEF in the aging population. Early adopter of tafamidis for ATTR-CM. Unique HF epidemiology with higher rates of hypertensive HFpEF. Sacubitril/valsartan available since 2020.
• India and developing countries: Rheumatic heart disease remains a major cause of HF. Limited access to advanced devices and transplant. Generic GDMT availability is improving. Chagas cardiomyopathy is a significant cause in Latin America.
• Australia/New Zealand: Strong HF registries, excellent transplant programs, early adoption of SGLT2i guidelines. Aboriginal and Torres Strait Islander populations have higher HF prevalence.

• Weight and symptom tracking: Many hospital systems offer patient portals with HF-specific dashboards. Simple spreadsheet or paper logs also work well.
• Medication reminders: Smartphone alarm apps, pill organizers, pharmacy auto-refill programs
• Low-sodium cooking resources: AHA’s low-sodium recipes, the DASH diet cookbooks, sodium tracking apps
• CardioMEMS: If you have an implanted PA pressure monitor, your daily readings are transmitted automatically to your HF team. Merlin.net and myMerlin apps for Abbott device patients.

Qiliqiangxin (QLQX) is an 11-herb traditional Chinese medicine formula that has been approved in China for the treatment of chronic heart failure. It is the first traditional medicine to demonstrate benefit in a large, randomized, placebo-controlled heart failure trial.

• The QUEST trial: Randomized 3,110 patients with HFrEF (EF ≤40%) across 133 hospitals in China, all on top of standard GDMT
• Primary endpoint met: Composite of heart failure hospitalization and cardiovascular death — HR 0.78 (95% CI 0.68–0.90, P<0.001)
• Published: Nature Medicine 2024; presented at ESC Congress 2023

The Japanese Heart Failure Society (JHFS) and Japanese Circulation Society (JCS) guidelines include distinct dosing recommendations for GDMT that reflect differences in body size, drug metabolism, and tolerability observed in Asian populations.

• Target doses for ACE inhibitors, ARBs, ARNIs, and beta-blockers are generally lower than AHA/ACC or ESC recommendations
• Japanese patients may achieve therapeutic benefit at lower doses, with higher rates of hypotension-related side effects at Western target doses
• SGLT2 inhibitor dosing is the same (dapagliflozin 10 mg, empagliflozin 10 mg) across all guidelines
• These considerations are relevant for patients of Asian descent receiving care in any country

Ivabradine, developed by Servier (France), selectively slows the heart rate by inhibiting the I_f (“funny”) channel in the sinus node without lowering blood pressure — a unique mechanism among heart failure drugs.

• SHIFT trial: Demonstrated an 18% reduction in the composite of cardiovascular death or heart failure hospitalization in HFrEF patients with heart rate ≥70 bpm in sinus rhythm
• ESC guidelines: Class IIa recommendation for selected HFrEF patients with heart rate ≥70 bpm despite maximally tolerated beta-blocker therapy
• Regional differences: Used more commonly in Europe than in the United States, where beta-blocker up-titration is generally prioritized first
• US guidelines (AHA/ACC/HFSA 2022): Class IIa, Level B-R recommendation for HFrEF patients in sinus rhythm with HR ≥70 bpm on maximum tolerated beta-blocker

• Milrinone (oral, chronic use) FAILED
  Oral milrinone, a phosphodiesterase-3 inhibitor that strengthens heart contraction, was tested for chronic outpatient HFrEF in the PROMISE trial (1991). It increased mortality by 28% compared to placebo despite improving symptoms short-term. The FDA never approved oral milrinone for chronic use. IV milrinone remains appropriate only for short-term hemodynamic support in acute decompensated HF.
• Vesnarinone FAILED
  Another oral inotrope tested for chronic HFrEF. The VEST trial (1998) was stopped early because vesnarinone at the higher dose (60 mg) increased mortality by 21%. At the lower dose (30 mg) there was no mortality benefit. Development was abandoned.
• Moxonidine FAILED
  A central sympatholytic agent intended to reduce harmful sympathetic nervous system overactivation in HFrEF. The MOXCON trial (2003) was stopped early due to excess deaths and hospitalizations in the moxonidine group. While sympathetic overactivation is a real problem in HF, this approach to reducing it proved harmful.
• Nesiritide (Natrecor) DE-ADOPTED
  Recombinant BNP given intravenously for acute decompensated HF. It was widely used in the early 2000s, but the ASCEND-HF trial (2011, over 7,000 patients) showed no meaningful benefit for dyspnea or mortality, with a trend toward worsening kidney function. Use dropped dramatically, and it was removed from clinical guidelines. The manufacturer discontinued it in 2017.
• Omecamtiv mecarbil (limited benefit) FAILED
  A cardiac myosin activator designed to strengthen heart contraction without increasing calcium (a safer mechanism than older inotropes). The GALACTIC-HF trial (2021, over 8,000 patients) met its primary endpoint with a modest 8% reduction in HF events, but showed no mortality benefit, and the clinical significance was questioned. The FDA issued a Complete Response Letter in 2023 and did not approve it. Development for HF has stalled.
• Routine intermittent inotrope infusions DE-ADOPTED
  Scheduled outpatient IV infusions of dobutamine or milrinone were once common for advanced HF patients. Multiple studies showed increased arrhythmias and mortality. Current guidelines recommend continuous inotropes only as palliative therapy or as a bridge to transplant/LVAD, never as routine intermittent “tune-ups.”
• Digoxin for mortality reduction DE-ADOPTED
  Digoxin (digitalis) was a cornerstone of heart failure treatment for over 200 years. The DIG trial (1997) showed it reduces hospitalizations but does not reduce mortality. With the arrival of ARNI, SGLT2 inhibitors, and MRAs — all of which reduce mortality — digoxin has been relegated to a minor role. It is now used only in select patients who remain symptomatic despite full GDMT optimization. Narrow therapeutic window and toxicity risk further limit its use.
• Calcium channel blockers (first-generation) for HFrEF WITHDRAWN
  Non-dihydropyridine calcium channel blockers (verapamil, diltiazem) are contraindicated in HFrEF because they weaken cardiac contraction and can worsen heart failure. Even the dihydropyridine amlodipine, while safe (PRAISE-1 trial), showed no mortality benefit. Calcium channel blockers should not be used specifically to treat HFrEF, though amlodipine or felodipine may be used cautiously for coexisting hypertension or angina if needed.

• HFrEF (Heart Failure with Reduced Ejection Fraction): Heart failure where the left ventricle cannot contract forcefully enough; ejection fraction is 40% or below.
• HFpEF (Heart Failure with Preserved Ejection Fraction): Heart failure where the left ventricle is stiff and cannot relax properly to fill with blood; ejection fraction is 50% or above.
• HFmrEF (Heart Failure with Mildly Reduced Ejection Fraction): An intermediate category with ejection fraction between 41% and 49%.
• GDMT (Guideline-Directed Medical Therapy): The combination of medications proven in clinical trials to improve survival and reduce hospitalizations in heart failure. For HFrEF, this includes four drug classes (ARNI or ACEi/ARB, beta-blocker, MRA, and SGLT2 inhibitor).
• ARNI (Angiotensin Receptor-Neprilysin Inhibitor): A combination drug (sacubitril/valsartan, brand name Entresto) that blocks harmful neurohormonal activation while boosting beneficial natriuretic peptides.
• MRA (Mineralocorticoid Receptor Antagonist): Medications (spironolactone, eplerenone, finerenone) that block aldosterone, reducing fluid retention, inflammation, and scarring in the heart.
• SGLT2i (Sodium-Glucose Co-Transporter 2 Inhibitor): Originally diabetes drugs (dapagliflozin, empagliflozin) now proven to benefit all forms of heart failure regardless of diabetes status. They promote sodium and glucose excretion and protect both heart and kidneys.
• CRT (Cardiac Resynchronization Therapy): A specialized pacemaker that coordinates the beating of both ventricles to improve pumping efficiency; used in HFrEF patients with wide QRS complex on ECG.
• ICD (Implantable Cardioverter-Defibrillator): A device that continuously monitors heart rhythm and delivers an electric shock to restore normal rhythm if a life-threatening arrhythmia is detected.
• LVAD (Left Ventricular Assist Device): A mechanical pump surgically implanted to help the weakened left ventricle pump blood; used as a bridge to transplant or as long-term destination therapy.
• ATTR-CM (Transthyretin Amyloid Cardiomyopathy): A specific cause of heart failure in which the transthyretin protein misfolds and deposits as amyloid in the heart muscle, causing stiffness and thickening.
• Ejection Fraction (EF): The percentage of blood pumped out of the left ventricle with each heartbeat. Normal is 55–70%. This number determines heart failure classification and guides treatment decisions.
• BNP / NT-proBNP: Blood biomarkers released by the heart when it is under stress. Elevated levels help diagnose heart failure and track its severity over time. Higher levels generally indicate worse heart failure.
• NYHA Class (New York Heart Association Functional Classification): A system for grading heart failure symptom severity from I (no limitation) to IV (symptoms at rest). Used to guide treatment decisions and assess prognosis.

• University of Utah Health — Heart Failure & Transplant Program: Comprehensive advanced heart failure center offering LVAD implantation, heart transplantation, ATTR-CM diagnosis and treatment, cardiac rehabilitation, and multidisciplinary HF care. The Amyloidosis Program provides specialized evaluation including bone scintigraphy and TTR stabilizer management. Main: (801) 581-2121 | Cardiology referral: (801) 585-7676
• Intermountain Heart Institute: Located at Intermountain Medical Center in Murray, Utah. One of the largest heart failure programs in the Intermountain West, offering advanced HF management, GDMT optimization, remote monitoring, mechanical circulatory support, and heart transplant evaluation. Additional HF clinics at Utah Valley Hospital and McKay-Dee Hospital. Main: (801) 442-2000

• Cleveland Clinic — Heart, Vascular & Thoracic Institute (Cleveland, OH): Consistently ranked among the top heart programs in the United States. Comprehensive heart failure, transplant, and LVAD program with extensive clinical trial participation and a dedicated cardiac amyloidosis center. Main: (216) 444-2200 | Heart failure appointments: (866) 289-6911
• Mayo Clinic (Rochester, MN): Nationally recognized heart failure and transplant program with expertise in ATTR-CM, genetic cardiomyopathies, and advanced imaging. Multi-site program with locations in Arizona and Florida. Appointments: (507) 284-2511
• Brigham and Women’s Hospital (Boston, MA): Harvard-affiliated advanced heart failure and transplant center. Major contributor to landmark HF clinical trials (PARADIGM-HF, DELIVER, EMPEROR). Strong cardiac amyloidosis program. Main: (617) 732-5500
• Duke University Medical Center (Durham, NC): Pioneering heart failure research program and transplant center. Home to the Duke Clinical Research Institute, which has led numerous HF trials. Comprehensive mechanical circulatory support and amyloidosis programs. Main: (919) 684-8111

• George E. Wahlen VA Medical Center (Salt Lake City, UT): Provides heart failure management, GDMT optimization, echocardiography, and cardiac rehabilitation for veterans. Coordinates referrals to University of Utah Health for advanced therapies (transplant, LVAD, ATTR-CM workup) when needed. Telehealth and home-based primary care programs available for veterans with limited mobility. Main: (801) 582-1565
• VA Palo Alto Health Care System (Palo Alto, CA): Advanced heart failure and transplant program in partnership with Stanford University Medical Center. LVAD and transplant evaluation for Western region veterans. Main: (650) 493-5000
• VA Greater Los Angeles Healthcare System (Los Angeles, CA): Cardiology section with HF management, GDMT optimization, and cardiac rehabilitation. Referral network for advanced therapies. Main: (310) 478-3711

• University of Ottawa Heart Institute (Ottawa, ON): Canada’s largest and most comprehensive cardiovascular research and treatment center. Advanced heart failure and transplant program, cardiac amyloidosis clinic, mechanical circulatory support, and extensive clinical trial portfolio. Main: (613) 761-5000
• Peter Munk Cardiac Centre — Toronto General Hospital (Toronto, ON): One of the world’s largest heart transplant centers, affiliated with the University of Toronto. Comprehensive advanced heart failure program including LVAD, transplant, cardiac amyloidosis, and participation in major international HF clinical trials. Main: (416) 340-4800
• Montreal Heart Institute (Montreal, QC): Leading Canadian cardiovascular center with advanced HF program, transplant, mechanical circulatory support, and amyloidosis evaluation. Strong clinical trial portfolio. Main: (514) 376-3330

• Royal Brompton & Harefield Hospitals (London, UK): One of Europe’s largest heart and lung centres. Advanced HF program including transplant, LVAD, and the National Amyloidosis Centre (NAC) at Royal Free Hospital for ATTR-CM diagnosis and management. Tel: +44 20 7352 8121
• Deutsches Herzzentrum Berlin (DHZB, Berlin, Germany): Leading European center for heart transplant and mechanical circulatory support with extensive LVAD experience and advanced HF clinical trials. Tel: +49 30 4593 1000
• National Cerebral and Cardiovascular Center (Suita, Osaka, Japan): Japan’s premier cardiovascular research hospital with specialized HF and ATTR-CM programs. Early adopter of tafamidis and advanced imaging protocols. Tel: +81 6 6170 1070

• Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022;145(18):e895–e1032.
• McDonagh TA, et al. 2023 Focused Update of the 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. Eur Heart J. 2023;44(37):3627–3639.
• Kittleson MM, et al. 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure with Preserved Ejection Fraction. J Am Coll Cardiol. 2023;81(18):1835–1878.
• McMurray JJV, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure (PARADIGM-HF). N Engl J Med. 2014;371(11):993–1004.
• McMurray JJV, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction (DAPA-HF). N Engl J Med. 2019;381(21):1995–2008.
• Packer M, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure (EMPEROR-Reduced). N Engl J Med. 2020;383(15):1413–1424.
• Solomon SD, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction (DELIVER). N Engl J Med. 2022;387(12):1089–1098.
• Anker SD, et al. Empagliflozin in heart failure with a preserved ejection fraction (EMPEROR-Preserved). N Engl J Med. 2021;385(16):1451–1461.
• Packer M, et al. Tirzepatide in heart failure with preserved ejection fraction and obesity (SUMMIT). N Engl J Med. 2024. Published online.
• Solomon SD, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction (FINEARTS-HF). N Engl J Med. 2024;391(16):1475–1485.
• Maurer MS, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy (ATTR-ACT). N Engl J Med. 2018;379(11):1007–1016.
• Gillmore JD, et al. Acoramidis in transthyretin amyloid cardiomyopathy (ATTRibute-CM). N Engl J Med. 2024;390(2):132–142.
• Fontana M, et al. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy (HELIOS-B). N Engl J Med. 2024. Published online.
• Teerlink JR, et al. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure (GALACTIC-HF). N Engl J Med. 2021;384(2):105–116.
• Armstrong PW, et al. Vericiguat in patients with heart failure and reduced ejection fraction (VICTORIA). N Engl J Med. 2020;382(20):1883–1893.
• Ponikowski P, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure (AFFIRM-AHF). Lancet. 2020;396(10266):1895–1904.